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Abstract
Background: Notwithstanding previous studies supporting independent associations between obstructive sleep
apnea (OSA) and prevalence of diabetes, the underlying pathogenesis of impaired glucose regulation in OSA
remains unclear. We explored mechanisms linking OSA with prediabetes/diabetes and associated biomarker
profiles. We hypothesized that OSA is associated with distinct alterations in glucose homeostasis and biomarker
profiles in subjects with normal (NGM) and impaired glucose metabolism (IGM).
Methods: Forty-five severely obese adults (36 women) without certain comorbidities/medications underwent
anthropometric measurements, polysomnography, and blood tests. We measured fasting serum glucose, insulin,
selected cytokines, and calculated homeostasis model assessment estimates of insulin sensitivity (HOMA-IS) and
pancreatic beta-cell function (HOMA-B).
Results: Both increases in apnea-hypopnea index (AHI) and the presence of prediabetes/diabetes were associated
with reductions in HOMA-IS in the entire cohort even after adjustment for sex, race, age, and BMI (P = 0.003). In
subjects with NGM (n = 30), OSA severity was associated with significantly increased HOMA-B (a trend towards
decreased HOMA-IS) independent of sex and adiposity. OSA-related oxyhemoglobin desaturations correlated with
TNF-a (r=-0.76; P = 0.001) in women with NGM and with IL-6 (rho=-0.55; P = 0.035) in women with IGM (n = 15)
matched individually for age, adiposity, and AHI.
Conclusions: OSA is independently associated with altered glucose homeostasis and increased basal beta-cell
function in severely obese adults with NGM. The findings suggest that moderate to severe OSA imposes an
excessive functional demand on pancreatic beta-cells, which may lead to their exhaustion and impaired secretory
capacity over time. The two distinct biomarker profiles linking sleep apnea with NGM and IGM via TNF-a and IL-6
have been discerned in our study to suggest that sleep apnea and particularly nocturnal oxyhemoglobin
desaturations are associated with chronic metabolic fluxes and specific cytokine stressors that reflect links between
sleep apnea and glucose metabolism. The study may help illuminate potential mechanisms for glucose
dysregulation in OSA, and resolve some controversy over the associations of OSA with TNF-a and IL-6 in previous
studies.
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Obstructive sleep apnea (OSA) and impaired glucose
metabolism (IGM) are closely linked to an epidemic of
obesity in Western society, and both are associated with
a significantly increased cardiovascular risk. Epidemiolo-
gic data from the Sleep Heart Health Study [1] suggested
that OSA is associated with glucose intolerance and insu-
lin resistance independent of obesity, and may lead to
type 2 diabetes mellitus. Yet the underlying mechanisms
for IGM in OSA and obesity remain less well understood.
Both increases in insulin resistance and decline in beta-
cell function play a role in the development of prediabetes
and subsequent type 2 diabetes [2]. Despite the well-
known links between OSA and glucose intolerance, the
studies examining associations between OSA and glucose
homeostasis have yielded mixed results. While several
clinic-based studies have demonstrated an independent
association between OSA and increased insulin resistance
[1,3-5], two case-control studies [6,7] did not find any evi-
dence to support the independent link between OSA and
insulin resistance. Moreover, information on the impact of
OSA on insulin secretion or other aspects of glucose
metabolism is scarce. In a recent study [8], we suggested
that hypoxic stress of OSA may be implicated in the devel-
opment of insulin resistance and steatohepatitis in severe
obesity. Here we extend our previous study to further elu-
cidate the interrelationships among OSA, impaired glucose
metabolism, and measures of inflammatory regulation in
severely obese patients.
A major impediment to investigating metabolic conse-
quences of OSA is inclusion of subjects with concomitant
prediabetes. The prediabetes itself is associated with both
insulin- and glucose resistance, decreased insulin sensitiv-
ity, and decreased beta-cell function [9]. Most previously
published studies evaluating glucose homeostasis in OSA
did not account for the presence of prediabetes. Further-
more, in studies prior to 2003, researchers relied upon less
strict criteria for prediabetes [10]. Therefore, it is not
known whether increases in insulin resistance and
decreases in beta-cell function observed in OSA are
related primarily to OSA or to the otherwise high preva-
lence of previously unrecognized concomitant prediabetes.
An increasing body of evidence suggests that OSA has
also been associated with elevations of inflammatory
cytokines particularly in those who are obese. However,
despite controlling for adiposity, results of several stu-
dies investigating associations between OSA and adipo-
cytokines such as tumor necrosis factor-alpha (TNF-a)
and interleukin-6 (IL-6) are inconclusive. Yet none has
examined associations between these biomarkers and
OSA in relatively healthy adults across a range of glu-
cose tolerances from normal to prediabetes and diabetes
while controlling for the degree of obesity.
The goal of the present study was to explore the
mechanisms and biomarker profiles linking OSA with
glucose dysregulation in severe obesity. We hypothe-
sized that OSA independent of obesity is associated with
distinct alterations in glucose homeostasis and distinct
biomarker profiles in NGM and IGM. To address this
hypothesis, we recruited a group of severely obese sub-
jects for study, since their adiposity made them prone to
disturbances in glucose homeostasis and inflammatory
biomarkers that could be associated with OSA.
Subjects and Methods
Study Design and Setting
This was a cross-sectional study conducted in 2003-
2009 in the Johns Hopkins Sleep Disorders Center and
the Clinical Research Unit at Johns Hopkins Bayview
Medical Center. The protocols were approved by the
Western Institutional Review Board. The research was
conducted in accordance with the ethical standards of
the institutional and national committee on human
experimentation. Written informed consent was
obtained from all subjects before participating in the
study.
Study Population
Participants were recruited from the Johns Hopkins
Center for Bariatric Surgery in Baltimore, MD. Inclusion
criteria were age >21 years and a body mass index
(BMI; defined as weight in kilograms divided by the
square of the height in meters) ≥35 kg/m
2.E x c l u s i o n
criteria included pregnancy, acute or chronic infectious
or inflammatory disease, unstable cardiovascular disease,
chronic obstructive pulmonary disease, asthma, history
of thyroid disease, heart attack, stroke or surgery during
the past 6 months, current systemic use of steroids,
non-steroidal anti-inflammatory drugs, antibiotics, anti-
virals, antirheumatic drugs, hormonal contraceptives or
other medications that may influence an individual’s
biomarker response to OSA and metabolic disturbances.
Of the 118 subjects initially recruited from the bariatric
clinic, 45 were identified for inclusion. Of the entire cohort
of 45 subjects, 36 (80%) were women (28 premenopausal,
8 postmenopausal) and 9 (20%) were men. Thirty subjects
(66.7%) had NGM and 15 (33.3%) had IGM.
Anthropometric measurements, overnight polysomno-
graphy (PSG), and blood tests were performed in all
study participants.
Metabolic Assessment
Obesity was considered mild if the BMI was 27-30 kg/m
2,
moderate if 30-35 kg/m
2, severe if 35-40 kg/m
2, morbid if
40-50 kg/m
2, super obesity if 50-60 kg/m
2,a n ds u p e r ,
super obesity if the BMI was >60 kg/m
2 [11].
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history of prediabetes or diabetes and a fasting serum
glucose level <5.6 mmol/L. IGM was defined if one of
the following was true: 1) a history of prediabetes or
diabetes, 2) current use of an anti-diabetic medication,
or 3) fasting serum glucose level ≥5.6 mmol/L.
Homeostatic model assessment (HOMA) was used to
quantify estimates of steady state insulin resistance
(HOMA-IR), insulin sensitivity (HOMA-IS), and pancrea-
tic beta-cell function (HOMA-B) as percentages of normal
reference populations [12]. The updated HOMA2 model
[13] incorporated in a computer program HOMA Calcula-
tor v2.2.2 [14] was utilized in this study. The model con-
sists of a number of improvements to the HOMA1
equations [12] with mathematical representations of the
tissues and organs involved in glucose regulation.
HOMA2 accounts for variations in hepatic and peripheral
glucose resistance [15], increases in the insulin secretion
curve for more hyperglycemic states, and introduces the
contribution of circulating proinsulin [13]. As HOMA is
based on steady state physiology, the HOMA2 model
includes limits for glucose 3-25 mmol/L and insulin
20-400 pmol/L. Values outside these limits are considered
non-steady state and cannot be assessed.
HOMA2 models could not be calculated for one man
with NGM (missing insulin data) and for three women
with IGM. One woman was taking exogenous insulin,
which precluded use of the HOMA to assess beta-cell
function. In two women, the insulin levels were outside
limits for HOMA calculators; one insulin value 15.6
pmol/L was below the HOMA lower limit, one value
416 pmol/L was above the upper limit.
Analytical Assay
A fasting blood sample was drawn on the morning after
completion of the sleep study. Serum was stored at
-80°C until assay. All samples and standards were run in
duplicate and analyzed in the same batches.
Enzyme-linked immunosorbent assay (ELISA) was
used for measurements of serum interleukin-1ß (IL-1ß),
high sensitive IL-6, interleukin-8 (IL-8), TNF-a,s o l u b l e
TNF-a receptor 1 (sTNFaR1), soluble TNF-a receptor
2( s T N F aR2) [MSD, Gaithersburg, MD], leptin and
soluble leptin receptor (R&D Systems, Inc., Minneapolis,
MN), adiponectin (Millipore, Inc., St. Charles, MO),
C-reactive protein (CRP) [R&D Systems, Inc., Minnea-
polis, MN], and insulin (Millipore Corp., Billerica, MA).
Serum concentrations of ghrelin were determined by
radioimmunoanalysis using commercial kits from Milli-
pore, Inc. (St. Charles, MO).
Intra-assay coefficients of variation (CV) were 7.79%
for IL-1ß, 7.79% for IL-6, 4.41% for IL-8, 7.71% for
TNF-a, 1.31% for sTNFaR1, 2.55% for sTNFaR2, 8.08%
for leptin, 3.1% for soluble leptin receptor, 2.11% for
adiponectin, and 5.17% for ghrelin. Inter-assay CVs were
5.96% for IL-1ß, 5.96% for IL-6, 14.92% for IL-8, 11.76%
for TNF-a, 12.64% for sTNFaR1, 6.45% for sTNFaR2,
3.87% for leptin, 7.7% for soluble leptin receptor, 1.65%
for adiponectin, and 6.69% for ghrelin.
Polysomnography
All subjects underwent a full-night sleep study to charac-
terize their sleep and breathing pattern. All physiologic
signals were digitally acquired by Somnologica software
(Somnologica Studio, Medcare Flaga, Reykjavik, Iceland).
Each recording was visually scored in 30-second epochs
according to standard criteria [16]. Respiratory events and
arousals were scored according to established criteria
[16-19]. Apnea was defined as a drop in the peak thermal
sensor excursion by ≥90% of baseline, lasting 10 seconds
or longer. Hypopneas were identified if the nasal pressure
signal excursions dropped by ≥30% of baseline for at least
10 seconds and there was a ≥4% desaturation from pre-
event baseline.
The number of apneas and hypopneas per hour of sleep
were calculated to obtain the apnea-hypopnea index (AHI).
The oxygen desaturation index (ODI) was calculated for
each subject as the total number of oxyhemoglobin desa-
turations ≥4% below the baseline level per hour of sleep.
OSA was diagnosed using the accepted criteria and
standards of the American Academy of Sleep Medicine
[17]. OSA was considered mild if the AHI was 5-15
events/hour, moderate if 15-30 events/hour, and severe
if ≥30 events/hour [17].
Statistical Analyses
The Shapiro-Wilk test was applied to test for a normal
distribution. Continuous variables with normal distribu-
tion were compared with use of a Student’s t test. Con-
tinuous variables with non-normal distributions were
compared with use of the Wilcoxon matched-pairs
signed-ranks test, the Wilcoxon rank-sum test, or the
Mood’s median test. The chi-square test was used to
examine patterns between categorical variables.
The Pearson product-moment correlation coefficient
(r), Spearman’s rank correlation coefficient (rho), and
multiple regression analyses were utilized to examine
relationships among the variables of interest. Coeffi-
cients of partial determination (partial R
2 values) were
calculated to explore relative effects of the variables on
an outcome measure in the model.
To achieve approximate normality, the AHI and not
normally distributed HOMA values were log-transformed
prior to analysis according to the formula log(x+1).T h e
back-transformed values with their original units are
reported for ease of interpretation.
Findings were considered to be statistically significant
at the 5% level. All statistical calculations were
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(StataCorp LP, College Station, TX).
Results
Sample Characteristics and Metabolic Assessment
Table 1 shows characteristics of study participants and
subgroups based on sex and glucose metabolism. The
cohort was predominantly female, middle-aged, with
both normal and impaired glucose metabolism, and had
wide ranges of OSA severity and clinically severe obe-
sity. Correlation analyses were utilized to identify vari-
ables and biomarkers associated with OSA.
Table 2 displays results of the bivariate analyses in all
study participants and in subgroups based on sex and
glucose metabolism. The OSA severity was associated
with male sex, central adiposity, and with alterations in
glucose homeostasis. Importantly, the correlations of
AHI with insulin and HOMA estimates observed in the
entire cohort were driven by significant correlations
found only in subjects with NGM.
Multivariable regression analyses were conducted to
determine whether unadjusted associations persisted
after controlling for potential confounders. In a model
adjusting for sex, race, age, and BMI, both increases in
AHI and the presence of prediabetes/diabetes were asso-
ciated with reductions in HOMA-IS (P =0 . 0 0 3 )i nt h e
entire cohort. The AHI explained 20.4% (P = 0.006) and
the IGM explained 13.8% (P = 0.026) of the variance in
HOMA-IS in this model. Similar linear associations with
HOMA-IS were observed when AHI was replaced by
ODI (P = 0.011), degree of oxyhemoglobin desaturation
associated with each disordered breathing event (ΔSaO2)
(P = 0.012), minimum oxyhemoglobin saturation during
sleep (MinSaO2)( P = 0.016) or variability of oxyhemo-
globin saturation during sleep as measured by SD and
CV (both P = 0.015).
To further explore the alterations in glucose homeos-
tasis associated with OSAi nN G M ,w ec o m p a r e d
HOMA estimates and insulin levels in the subjects with
NGM stratified by OSA severity. Utilizing an AHI cut-
off of 15 events/hour, we found significant elevations in
median HOMA-IR, HOMA-B, and insulin levels and
significant reductions in median HOMA-IS in subjects
with AHI > 15 events/hour compared to those with
AHI < 15 events/hour (Figure 1) despite no significant
differences in BMI (P = 0.213) and age (P = 0.450).
Nevertheless, the individuals with AHI > 15 events/hour
had larger neck circumference (P = 0.030) and sagittal
abdominal diameter (P = 0.027), and were more likely
to be male (P = 0.013). No significant differences were
observed for CRP or adipokine levels between the two
NGM subgroups. Bivariate and linear regression ana-
lyses (Table 2 and Figure 2) confirmed that increases in
HOMA-B and insulin levels were strongly associated
with OSA severity in both men and women with NGM
and for the NGM group as a whole.
Even after adjusting for sex and BMI, the increases in
AHI in subjects with NGM were associated with
increases in HOMA-B (P <0 . 0 0 1 ) ,H O M A - I R( P <
0.001), and insulin levels (P <0 . 0 0 1 ) .R e s u l t sw e r es i m i -
lar when BMI was replaced by waist circumference in
the regression models. Other measures of OSA severity,
including ODI, MinSaO2, ΔSaO2,a n dS Da n dC Vo f
oxyhemoglobin saturation during sleep were significantly
linearly associated with increased HOMA-B in subjects
with NGM independent of sex and BMI. No significant
associations were found between HOMA estimates and
mean oxyhemoglobin saturation during sleep.
Matched-pair Case-control Analysis of Biomarker Profiles
Employing a matched-pair design, we further explored
biomarker profiles associated with OSA in subjects with
NGM and IGM. We have identified 15 female-female
pairs matched individually for age (P = 0.231), BMI (P =
0.215), waist circumference (P = 0.149), and AHI (P =
0.191). The individually matched pairs were distinct on
the basis of glucose metabolism status and fasting
serum glucose (P < 0.001). The case group consisted of
12 women (80%) with prediabetes and 3 (20%) with type
2 diabetes. The control group consisted exclusively of
women with NGM.
I nau n i v a r i a t ea n a l y s i s ,w ec o n f i r m e dt h a ts u b j e c t s
with IGM had reductions in both HOMA-B (P =0 . 0 3 6 )
and HOMA-IS (P =0 . 0 4 1 )c o m p a r e dt ot h o s ew i t h
NGM. There were trends towards increased insulin
levels (P =0 . 0 6 9 )a n di n c r e a s e dH O M A - I R( P =0 . 0 5 0 )
in the case group. No significant differences were
observed between the case and control groups for the
absolute cytokine levels.
Through bivariate association analyses, we identified
two distinct biomarker profiles associated with OSA in
subjects with NGM (Figure 3A) and IGM (Figure 3B). In
the control group with NGM, the mean low oxyhemoglo-
bin saturation during sleep (LowSaO2)a n dΔSaO2 were
strongly correlated with TNF-a and TNF-a was strongly
correlated with sTNFaR2 (rho = 0.73; P =0 . 0 0 2 ) ,
whereas in the case group with IGM, there was a strong
correlation of LowSaO2 and ΔSaO2 with IL-6. Further-
more, the IL-6 in the case group was strongly positively
associated with BMI and leptin-to-leptin receptor ratio.
In a multivariate linear regression analysis in the con-
trol group, the LowSaO2 was associated with TNF-a
even after adjustment for BMI and age (P = 0.011).
When BMI was replaced by waist circumference in the
regression analysis, the LowSaO2 maintained an inde-
pendent association with TNF-a (P = 0.013).
In the case group, the IL-6 was positively linearly
associated with leptin-to-leptin receptor ratio, BMI, and
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Page 4 of 11Table 1 Clinical characteristics of study participants
All Men with NGM Women with NGM Women with IGM
(n = 45) (n = 9) (n = 21) (n = 15)
Age, years 36 (34-46) 36 (34-39) 36 (31-48) 42 (34-55)
White race, n (%) 30 (66.7) 5 (55.6) 14 (66.7) 11 (73.3)
Anthropometrics
BMI, kg/m 47.3 (43.4-50.8) 49.1 (46.1- 55.2) 44.5 (40.5-48.2) 47.9 (43.4-52.3)
Severely obese, n (%) 6 (13.3) 0 (0) 5 (23.8) 1 (6.7)
Morbidly obese, n (%) 26 (57.8) 5 (55.6) 12 (57.1) 9 (60)
Super obese, n (%) 12 (26.7) 4 (44.4) 3 (14.3) 5 (33.3)
Super, super obese, n (%) 1 (2.2) 0 (0) 1 (4.8) 0 (0)
Neck, cm 41 (39.1-45.5) 49.2 (45.2-53) 39.4 (37-41.5) 41.3 (40.2-48)
Waist, cm 131.1 (122.3-144.2) 152 (143.7-161.8) 122.8 (113.6-134.3) 131.5 (125-136)
Waist-to-hip ratio 0.93 (0.87-0.98) 1.05 (0.98-1.09) 0.92 (0.86-0.96) 0.93 (0.89-0.94)
Sagittal abdominal diameter, cm 31 (28.5-35) 35 (29-36) 30 (28-33) 32 (29-35)
Metabolic outcomes
Glucose, mmol/L 5.2 (4.8-5.8) 4.8 (4.7-5.2) 4.8 (4.6-5.1) 6.2 (5.8-6.8)
Insulin, pmol/L 89 (45.5-116.6) 107.6 (70.4-168.4) 75.9 (44.9-91.8) 97.3 (69.7-127)
HOMA-IR, % 1.7 (1-2.2) 2.0 (1.3-3.1) 1.4 (0.8-1.7) 2.0 (1.6-2.6)
HOMA-IS, % 60 (45.3-104.1) 49.6 (33.15-96.9) 71.8 (58.9-121.8) 50.9 (38.3-65.5)
HOMA-B, % 110.4 (90.3-159) 152.2 (112.05-210.1) 134.1 (97.8-173.4) 97.5 (80.7-109.2)
CRP, mg/L 8.1(4.8-11) 6.8 (4.5-9.2) 7.3 (3.7-10.1) 9.6 (7.6-14.3)
Adipocytokines
IL-1ß, pg/mL 0.41 (0.38-0.5) 0.44 (0.4-0.56) 0.4 (0.36-0.5) 0.41 (0.38-0.48)
IL-6, pg/mL 1.95 (1.33-2.69) 1.63 (0.96-2.18) 1.67 (1.33-2.63) 2.33 (1.49-3.98)
IL-8, pg/mL 10.85 (8.36-13.15) 11.41 (10.85-13.15) 8.98 (6.9-13.24) 11.84 (9.16-12.99)
TNF-a, pg/mL 2.46 (2.03-3.16) 3.1 (2.36-3.2) 2.3 (1.93-3.45) 2.5 (2.13-2.96)
sTNFaR1, ng/mL 3.25 (2.28-4.33) 2.78 (2.02-4.30) 3.24 (2.18-4.11) 3.65 (2.79-4.41)
sTNFaR2, ng/mL 5.13 (4.22-6.72) 5.17 (4.16-6.53) 4.54 (4-6.62) 6.23 (4.55-6.78)
Leptin, μg/L 73.5 (56.7-94.9) 48.4 (43.4-61.5) 81.3 (72.3-103.0) 85.1 (47.2-95.9)
Leptin receptor, μg/L 16.2 (14.5-18.6) 14.5 (13.4-15.7) 16.4 (16.0-18.6) 16.6 (15.1-21.2)
Ghrelin, pg/mL 736.7 (589-983.2) 622.6 (533.8-720.7) 682.5 (573.6-946.7) 900.2 (690.9-1091.1)
Adiponectin, μg/mL 8.4 (6-10.6) 7.4 (3.6-9.1) 10.2 (7.7-11.6) 6.8 (5.8-11.4)
Sleep architecture
Total sleep time, min 398 (365-436) 359 (338-403) 398 (365-436) 412 (373-460)
Sleep efficiency, % 87 (81.8-93.2) 89 (79.7-96.5) 86 (83-91) 90 (84.5-96)
WASO, min 37.5 (16.5-71) 43.1 (13.5-81.5) 40.5 (16.5-58.5) 29.2 (16.5-71)
N1, % 10.6 (7.7-16.2) 11.0 (8.7-24.9) 12.7 (8.1-16.3) 8.4 (5.2-13.8)
N2, % 59.7 (53.4-65.3) 55.3 (52.1-66.4) 55.7 (48.7-63.8) 64.3 (59.9-68.5)
N3, % 11.1 (2.4-16.7) 2.9 (0-11.2) 16.5 (2.4-19.7) 10.3 (5.4-13.1)
REM sleep, % 15.6 (11.2-18.9) 15.9 (14.2-19.9) 14.4 (10.4-17.7) 16.6 (12.9-22.3)
PSG results
Total AHI, events/h 14.2 (6.4-22.9) 48 (22.5-71) 9 (4.2-16.5) 16.1 (4.9-22.9)
Obstructive apnea index, events/h 11.9 (5.5-18.9) 31.3 (17.7-57.6) 7.4 (4.2-11.9) 14.3 (4.9-18.3)
Central apnea index, events/h 0.24 (0-0.85) 0.41 (0-1.42) 0.25 (0-1.06) 0.23 (0-0.64)
Mixed apnea index, events/h 0.02 (0-0.39) 0.25 (0-0.75) 0 (0-0.36) 0 (0-0.33)
NREM AHI, events/h 9.6 (4.4-17.5) 44.1 (21.3-74.4) 5.2 (2.8-12) 9.6 (3-15.1)
REM AHI, events/h 32.3 (10.5-50.3) 53.4 (34.15-75.15) 23.3 (5.4-38.8) 32.8 (17.3-50.3)
▪ No OSA, n (%) 10 (22.2) 0 (0) 6 (28.5) 4 (26.7)
▪ Mild OSA, n (%) 14 (31.1) 2 (22.2) 9 (42.9) 3 (20)
▪ Moderate OSA, n (%) 13 (28.9) 2 (22.2) 5 (23.8) 6 (40)
▪ Severe OSA, n (%) 8 (17.8) 5 (55.6) 1 (4.8) 2 (13.3)
ODI, events/h 7.7 (3.8-16.6) 27.8 (10.3-69.6) 4.3 (2.2-9.4) 9.3 (4.2-18.4)
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of IL-6 with leptin-to-leptin receptor ratio, BMI, and
AHI persisted after adjustment for age (P <0 . 0 0 1 ) .I n
this model, the leptin-to-leptin receptor ratio explained
the highest proportion of the variance of IL-6 (52.8%;
P = 0.007). The BMI explained 48.4% (P =0 . 0 1 2 )a n d
the AHI 44.1% (P = 0.019) of the variance of IL-6 in the
case group when all other variables were included in the
model. Results were similar when BMI was replaced by
waist circumference in the regression model (P < 0.001).
Discussion
There were three major findings in the present study.
First, as expected OSA severity was associated with
alterations in glucose homeostasis in the entire cohort
of severely obese men and women across a range of glu-
cose tolerances. The observed associations of OSA
severity with alterations in glucose homeostasis were,
however, driven by significant correlations found only in
the subjects with NGM. Second, a stratified analysis
based on glucose metabolism confirmed the indepen-
dent linear association between OSA severity and
increased basal pancreatic beta-cell function in subjects
with NGM but not in those with prediabetes and dia-
betes. Third, we identified two distinct biomarker pro-
files associated with OSA in subjects with NGM and
IGM that may reflect pathophysiology of glucose dysre-
gulation in OSA and severe obesity.
Our study may help resolve inconsistencies in the cur-
rent literature regarding the relationship between OSA
and glucose homeostasis [1,3-7]. Several lines of evi-
dence have emerged from our study to suggest that
accounting for presence of prediabetes in studies investi-
gating the alterations in glucose homeostasis in patients
with OSA is highly relevant to achieving a better under-
standing of the underlying pathophysiology linking the
t w od i s o r d e r s .F i r s t ,t h ei n d e p e n d e n ta s s o c i a t i o n so f
OSA severity with increased beta-cell function in NGM
were found in our study and highlight the importance
of a compensatory increase in insulin secretion as a
mechanism through which beta-cell adaptation to
increased insulin resistance occurs [20]. Second, our
study demonstrated that subjects with IGM had both
reduced beta-cell function and decreased insulin sensi-
tivity, which confirms previous reports of a decline in
pancreatic beta-cell function in prediabetes [2,9,20].
Table 1 Clinical characteristics of study participants (Continued)
MeanSaO2, % 94.9 (93.5-95.9) 94.5 (89.4-95.9) 95.1 (93.7-95.9) 95.2 (93.5-95.4)
LowSaO2, % 91.4 (89.8-92.7) 90.1 (83-91.9) 92.5 (90.1-93.2) 91.6 (88.0-92.6)
MinSaO2, % 85 (82-88) 82 (68-85) 87 (83-88) 84 (72-88)
ΔSaO2, % 4.5 (4-5) 4.9 (4.8-11.3) 4.2 (3.6-4.6) 4.6 (4.0-6.6)
*Data are expressed as medians (IQR) if not otherwise stated. NGM, normal glucose metabolism. IGM, impaired glucose metabolism. WASO, wake after sleep
onset. N1, N2, N3, stages of NREM sleep.
Table 2 Correlations of OSA severity with clinical characteristics
All (n = 45) Women (n = 36) Men
+ (n = 9) All NGM (n = 30) Women NGM (n = 21) Women IGM (n = 15)
AHI with:
male sex 0.49** –– 0.59** ––
BMI 0.29 0.29 -0.42 0.33 0.32 0.16
neck circumference 0.56** 0.53** -0.02 0.57** 0.57* 0.47
waist circumference 0.46** 0.35* -0.15 0.54** 0.41 0.19
sagittal abd. diameter 0.32* 0.42* -0.39 0.48* 0.70** -0.04
insulin 0.51** 0.49** 0.71* 0.63** 0.50* 0.48
HOMA-IR 0.47** 0.44* 0.72* 0.54** 0.48* 0.35
HOMA-B 0.43* 0.35* 0.71* 0.63** 0.64** -0.10
HOMA-IS -0.47** -0.45* -0.67 -0.55** -0.48* 0.36
leptin -0.39* -0.24 -0.15 -0.46* -0.22 -0.23
adiponectin -0.25 -0.16 -0.15 -0.46* -0.36 0.15
LowSaO2 with:
TNF-a -0.29 -0.35* -0.22 -0.31 -0.44* -0.13
sTNFaR2 -0.23 -0.34* -0.001 -0.18 -0.47* -0.28
IL-6 -0.20 -0.18 -0.66 -0.01 0.19 -0.55*
The Pearson product-moment correlation coefficients and Spearman’s rank correlation coefficients. NGM, normal glucose metabolism; IGM, impaired glucose
metabolism; AHI, apnea-hypopnea index; LowSaO2, mean low oxyhemoglobin saturation during sleep.
*P < 0.05; **P < 0.005
+Men with NGM only
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Page 6 of 11This finding also suggests that reduced pancreatic beta-
cell function in patients with moderate to severe OSA
reported in a previous study [21] may have been due to
the presence of coexistent prediabetes particularly in the
patients with moderate to severe OSA. Third, there
were no linear associations between OSA severity and
HOMA estimates in the subjects with IGM compared to
individually matched controls with NGM. These find-
ings strongly suggest that prediabetes and diabetes
rather than OSA are directly associated with reduced
beta-cell function in patients with IGM and severe
obesity.
Our findings further suggest that pancreatic beta-cell
response to OSA differs in subjects with NGM and
IGM. Although both groups of severely obese indivi-
duals in our study were considerably hyperinsulinemic
and insulin resistant, consistent with previous findings
relating abdominal fat distribution to insulin resistance
[22], OSA was directly associated with increased insulin
resistance only in the subjects with NGM. It should be
recognized that increased basal insulin levels are not an
accurate reflection of beta-cell insulin secretion. In type
2 diabetes, basal proinsulin immunoreactivity contri-
butes approximately 2-3 times more to insulin immu-
noreactivity than in healthy subjects [23]. Thus, the
observed hyperinsulinemia in IGM might reflect incom-
plete processing of proinsulin to insulin with a combina-
tion of high proinsulin levels and low or normal true
insulin levels. Although it is still not known whether
nocturnal hypoxemia and increased beta-cell secretory
demand are associated with a progressive increase in
proinsulin/immunoreactive insulin ratio over time, data
from our study suggest that OSA contributes to insulin
resistance that imposes an excessive functional demand
on pancreatic beta-cells, which may lead to their
exhaustion and impaired secretory capacity over time.
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Figure 1 HOMA estimates and insulin levels in subjects with normal glucose metabolism stratified by OSA severity. The OSA severity
stratification was based on AHI 15 events/hour. Box plots displays boxes bordered at the 25
th and 75
th percentiles of the y variable with a
median line at the 50
th percentile. Whiskers extend from the box to the upper and lower adjacent values and are capped with an adjacent line.
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Page 7 of 11Biomarker profiles associated with OSA via TNF-a
and IL-6 have been discerned in our study, which can
illuminate potential mechanisms for glucose dysregula-
tion in OSA. TNF-a and IL-6 are critical elements in
inflammatory responses. It has been shown previously
that TNF-a stimulates secretion of IL-6 via an NF-
kappaB-dependent pathway [24]. The opposite regula-
tion of TNF-a and IL-6 has also been demonstrated in
a recent study in rats [25] where paradoxical sleep
deprivation caused an increase in serum corticosterone
levels, which was associated with up-regulation of IL-6
in retroperitoneal adipose tissue and downregulation of
TNF-a in mesenteric adipose tissue. TNF-a and IL-6
levels have been reported by others to be increased in
patients with OSA [3,26-28] and in those with left ven-
tricular diastolic dysfunction and glucose metabolism
disorders [29]. However, no differences were found in
other studies investigating associations of OSA with the
cytokines [30-32]. Substantial experimental evidence and
cross-sectional data suggest that IL-6 is associated with
hyperglycemia, insulin resistance, and overt type 2 dia-
betes [33,34]. Furthermore, elevated IL-6 levels predicted
the development of type 2 diabetes in a prospective
case-control study [35], supporting a possible role for
inflammation in diabetogenesis. Yet to date, there is no
prospective study that has explored a possible role of an
OSA triggered NF-kappaB-mediated TNF-a-induced
IL-6 gene expression in determining glucose tolerance
status in obese persons with OSA over time. Our find-
ings suggest that OSA is closely associated with IL-6
production in IGM, whereas in the absence of IGM, it is
associated with TNF-a. Importantly, our results further
showed additional close associations of IL-6 with BMI
and leptin-to-leptin receptor ratio in IGM. This finding
supports the major role that IL-6 plays in obesity and
extends it to pathophysiological processes linking obe-
sity to IGM via leptin resistance and OSA. Finally, the
finding of the two biomarker profiles associated with
OSA in NGM vs. IGM may help resolve some contro-
versy over the associations of OSA with TNF-a and
IL-6 in previous studies.
There are several limitations to our study that should
be considered in relation to the findings. First, its cross-
sectional design precludes inferences regarding causality.
Second, strict inclusion criteria and a substantially lower
number of male subjects in bariatric clinic cohorts hin-
dered enrollment of men with IGM in this study. Yet
despite the small sample size of men with NGM, the
observed associations between OSA severity and HOMA
estimates were similar to those observed in women.
Additionally, our results are consistent with the previous
reports of sexual dimorphism in leptin levels [36,37].
Third, although the use of the updated HOMA2 model
has been validated against a number of independent mea-
sures of insulin sensitivity and beta-cell function [38-40],
as with all models, the data need to be interpreted with
c a u t i o n .A l s o ,i ts h o u l db er e c o g n i z e dt h a tH O M Ai sa
measure of basal insulin sensitivity and basal beta-cell
function and, in contrast to insulin-glucose clamps, is not
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Figure 2 Associations between OSA severity and insulin
homeostasis in subjects with normal glucose metabolism.
Figures 2A-C illustrate predictions of HOMA-IR, HOMA-B, and insulin
levels calculated from log-transformed AHI using a linear regression
in women (solid diamond) and men (solid triangle) with normal
glucose metabolism. The thick line represents the line of best fit for
a set of data points. The shaded gray area represents the 95%
confidence interval around the best-fit line.
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Page 8 of 11intended to give information about the stimulated state.
Finally, in our study, we did not perform oral glucose tol-
erance tests in all subjects. Therefore, the exact classifica-
tion of glucose tolerance is impossible.
Conclusions
Despite the limitations, our study demonstrated that
OSA is independently associated with altered glucose
homeostasis and increased basal pancreatic beta-cell
function in severely obese adults with NGM. The
findings suggest that moderate to severe OSA imposes
an excessive functional demand on pancreatic beta-cells,
which may lead to their exhaustion and impaired secre-
tory capacity over time. The two distinct biomarker pro-
files discerned in our study suggest that OSA and
particularly nocturnal oxyhemoglobin desaturations are
associated with chronic metabolic fluxes and cytokine
stressors that reflect links between OSA and glucose
metabolism. The study may help illuminate potential
mechanisms for glucose dysregulation in OSA, and
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Figure 3 Biomarker profiles associated with OSA in normal vs. impaired glucose metabolism. Figure 3A presents the correlations of
LowSaO2 and ΔSaO2 with TNF-a level (solid diamond) in the control group of 15 women with normal glucose metabolism. Figure 3B displays
the correlations of LowSaO2 and ΔSaO2 with IL-6 level (solid circle) and the correlations of IL-6 with BMI (solid square) and leptin-to-leptin
receptor ratio (solid triangle) in the case group of 15 women with impaired glucose metabolism. The fitted curve represents a linear regression fit
between the two variables. r = Pearson product-moment correlation coefficient; rho = Spearman’s rank correlation coefficient.
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Page 9 of 11resolve some controversy over the associations of OSA
with TNF-a and IL-6 in previous studies. Further pro-
spective studies are needed to explore the impact of
OSA on pancreatic beta-cells, and to further elucidate
the dynamic interactions between the adipocytokines
linking sleep apnea with glucose metabolism.
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